Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

被引：20

作者：

MacKay, Helen J. ^{[1
]}

Levine, Douglas A. ^{[2
]}

Bae-Jump, Victoria L. ^{[3
]}

Bell, Daphne W. ^{[4
]}

McAlpine, Jessica N. ^{[5
,6
]}

Santin, Alessandro ^{[7
]}

Fleming, Gini F. ^{[8
]}

Mutch, David G. ^{[9
]}

Nephew, Kenneth P. ^{[10
]}

Wentzensen, Nicolas ^{[11
]}

Goodfellow, Paul J. ^{[12
,13
]}

Dorigo, Oliver ^{[14
]}

Nijman, Hans W. ^{[15
]}

Broaddus, Russell ^{[16
]}

Kohn, Elise C. ^{[17
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] NYU, Langone Laura & Isaac Perlmutter Canc Ctr, Dept OB GYN, Div Gynecol Canc, New York, NY USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Gynecol Oncol, Chapel Hill, CA USA

[4] NHGRI, Reprod Canc Genet Sect, Canc Genet & Comparat Genom Branch, NIH, MSC 8000, Bethesda, MD USA

[5] Univ British Columbia, Vancouver, BC, Canada

[6] BC Canc Agcy, Div Gynecol Oncol, Vancouver, BC, Canada

[7] Yale Sch Med, Dept Gynecol Obstet & Reprod Sci, New Haven, CT USA

[8] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL USA

[9] Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA

[10] Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA

[11] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[12] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA

[13] Ohio State Univ, Dept Obstet & Gynecol, Columbus, OH 43210 USA

[14] Dept Obstet & Gynecol, Div Gynecol Oncol, Stanford, CA USA

[15] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol, Groningen, Netherlands

[16] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA

[17] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Rockville, MD USA

来源：

ONCOTARGET | 2017年 / 8卷 / 48期

关键词：

endometrial cancer; molecular targets; PHASE-II TRIAL; UTERINE SEROUS CARCINOMA; REGULATORY T-CELLS; MEGESTROL-ACETATE; TUMOR-SUPPRESSOR; BETA-CATENIN; CLEAR-CELL; IMMUNOHISTOCHEMICAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE; HER2; AMPLIFICATION;

D O I：

10.18632/oncotarget.19961

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

引用

页码：84579 / 84594

页数：16

共 2 条

[1] Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting Taking Endometrial Cancer Trials Into the Translational Era
Creutzberg, Carien L.
Kitchener, Henry C.
Birrer, Michael J.
Landoni, Fabio
Lu, Karen H.
Powell, Melanie
Aghajanian, Carol
Edmondson, Richard
Goodfellow, Paul J.
Quinn, Michael
Salvesen, Helga B.
Thomas, Gillian
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08) : 1528 - 1534
[2] Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting Report
Harkenrider, Matthew M.
Markham, Merry Jennifer
Dizon, Don S.
Jhingran, Anuja
Salani, Ritu
Serour, Ramy K.
Lynn, Jean
Kohn, Elise C.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (11): : 1081 - 1088

← 1 →